<DOC>
	<DOCNO>NCT01454622</DOCNO>
	<brief_summary>The purpose study evaluate bioequivalence fix dose combination ( FDC ) tablets canagliflozin metformin immediate release ( IR ) comparison individual component canagliflozin metformin IR .</brief_summary>
	<brief_title>A Study Assess Bioequivalence 2 Fixed Dose Combination ( FDC ) Tablets Canagliflozin Metformin Immediate Release ( IR ) ( 50 mg/1,000 mg ) With Respect Individual Components Canagliflozin ( 1 x 100 mg ) Metformin IR Tablets ( 2 x 1,000 mg ) Healthy Volunteers</brief_title>
	<detailed_description>This open-label ( identity study drug know volunteer study staff ) , single-center study evaluate bioequivalence canagliflozin metformin IR administer orally ( mouth ) individual component ( ie , separate tablet canagliflozin metformin IR ) ( Treatment A ) administer fixed-dose combination ( FDC ) tablet ( ie , canagliflozin metformin IR contain tablet ) ( Treatment B ) . Healthy volunteer participate study randomly ( chance ) assign receive Treatment A follow Treatment B Treatment B follow Treatment A washout period approximately 15 day treatment .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Body mass index ( BMI ) 18.5 30 kg/mÂ² ( inclusive ) body weight less 50 kg History current medical illness , abnormal value hematology clinical chemistry laboratory test , abnormal physical examination , vital sign 12lead electrocardiogram ( ECG ) deem clinically significant Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Canagliflozin ( JNJ-28431754 )</keyword>
	<keyword>Metformin IR</keyword>
</DOC>